CML
Conditions
Interventions
Males have to collect seminal fluid at two different time points with 1 month between collection points. Blood samples will be drawn at the same intervals, within one hour of collection of semen sampl
Sponsors
VU University Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: • male patients • aged >18 years • use of nilotinib for a minimal period of 1 month in chronic phase of CML • willing and capable of donating a semen sample for pharmacological analysis
Exclusion criteria
Exclusion criteria: • Refractory CML with persistent leucocytosis • Sterilisation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of nilotinib present in seminal fluid in relation to the plasma concentration. | — |
Secondary
| Measure | Time frame |
|---|---|
| Calculated maximal concentration nilotinib absorbed by the partner, using the volume of distribution of the tyrosine kinase inhibitors and the percentage in seminal fluid found in this study. | — |
Contacts
Public ContactM.A. Kuijvenhoven
Outcome results
None listed